Never fails to disappoint. Q1 2017 results were well below projections. Essentially no growth in revenues. Actual earnings were about 1 cent per share. Tangible book value is now below $1 per share. The only reason the stock is above $5 is because of targeted share buybacks. Given its liabilities, for how long will the company afford to spend its dwindling cash on buybacks?
The Subway Trader: Trading Stocks and Making Money
Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
Ronan here, so shut your gob and listen: 1. Empty warehouses, no worries, I still get me rent. 2.Inventory write downs, standard procedure after St. Paddy's. 3. You want $20 ps, no problem, 1 fer 4 split coming soon! Cheers, Ronan
You won’t find a more consistent alert service than ExplosiveOTC, free reports have been uncovering some of the biggest plays from across the markets. Check them out today. www.explosiveotc.com
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.2 In other words, the correlation coefficient of the other stock
Did anyone else see $TRIB report from http://yugestocks.com/?s=TRIB ? It had some interesting information. Investing day trading. Aigner's axiom: no matter how well you perform your job
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
Pathetic Q4 results. A company in decline. Total revenues for Q4, 2016 were $23.7m which compares to $24.9m in Q4, 2015, a decrease of $1.2m.
Point-of-Care revenues for Q4, 2016 decreased from $5.4m to $4.0m when compared to Q4, 2015, a decline of 27.3%. This is due to the normal fluctuation patterns which impact HIV sales in Africa. Clinical Laboratory revenues increased to $19.7m, which represents an increase of 1.2% compared to Q4, 2015.
Ronan and his management team are awful, just awful IMHO. A disgrace to Irish business professionals all over the world.
From the earning conference call: Ronan O'Caoimh's gobbledygook answering question about strategic alternatives for the Meritas platform:
We don't have any update really on this, and I mean our alternatives remain as they were before, basically sell it, and I think we get a huge amount for us in all the circumstance. I think the experience, I mean we bought this technology for $12 million and I think we probably haven't added to its value in the context of what happened. So, like it really, I like it really what we'll do and we can basically do a joint venture with somebody where we are both involved or we can license it out for many applications, or alternatively we can continue to look to identify you know a useful and sensible parameter to put on us. So, basically look for a winner that we can put on this. So, those are alternatives. We continue to kind of explore those various alternatives and, so it sounds like we don't have anything to report at this time. But what I will say is that, is that we believe it's a very a valuable platform. And we have – I think just about any parameter can work successfully on it. It's possibly unfortunate that we selected probably the most difficult of all Troponin, and put that and this is a very useful tool in our armory as we move forward we believe and have no updates.
How low can it go? Since TRIB is a very low growth company (mid single digit), it should be valued at most at forward P/E ~ 12, which amounts to about $5. The tangible book value is only about $1.5/sh so it provides little support.
Is there still any hope for the Meritas platform? Internal review that would take 9-12 months... - laughable. "The Meritas platform has many potential applications in the point-of-care arena, and thus the company has embarked on an internal review process to determine the best future opportunity for this technically excellent platform. This process is expected to take between 9 and 12 months."
massive write down to be announced next week. Until that's behind us the stock price is vulnerable to the downside as no one will be buying going into earnings. If revenue for the quarter is north of $26 million it's a buying opportunity for sure. Less than $25 million and a dump it IMHO
lots of investigations but no law suits yet
what's the story with the legal investigation...is there a case?
I also received an alert for $TRIB from http://monstastocks.com/?s=TRIB , any ideas? Hutchins' law: you can't out-talk a man who knows what he's talking about. Making money day trading.
Monsta Stocks: Trading Stocks and Making Money
Stock alerts from the Monsta Stocks. Stock trading, making money and always looking for the next big money maker.
Massive write down coming from closing of Troponin investment. 4th Q will be reported in a couple of weeks and hopefully they report revenue north of $26 million or it won't be good. I agree with others on this board that management don't care too much about shareholders and have done a terrible job with this company IMHO
Very difficult to see TRIB not making a big run north now that it's pulled back this much. performance % (today) is now -0.96%. Ive been struggling with this stock lately. Some of my other trades have been from aw-esomeSTOCKS which are working out pretty well.
Is this company basically dead now? As an investment case anyway. Will it just be stuck at ~$7 until the next crappy update and excuses before it drops further?